2024 Japan pharma market year in review

6 January 2025

Patrick Branch, head of Japan and APAC business development at Nxera Pharma (TYO: 4565), provides a summary of the year in the important eastern market. An expert on pharma in Japan, he was previously a partner and Tokyo office co-head at L.E.K. Consulting, a global strategy consulting firm.

Summary – For many, a year to remember; for some, a year to forget

2024 was another exciting year for Japan’s pharma market. Underneath the somewhat stodgy surface, we saw a lot of dynamism and many exciting developments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK